Company dossier
Biocon
NSE:BIOCON · ISIN INE376G01013
- Close
- Unavailable Date unavailable
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Biocon
Financials
Structured filings
Exchange XBRLReported financial periods
| Metric | Quarter · FY26 · 31 Mar 26 | FY26 · 31 Dec 25 | Half year · FY26 · 30 Sept 25 | Quarter · FY26 · 30 Jun 25 | FY25 · 31 Mar 25 | Quarter · FY25 · 31 Dec 24 |
|---|---|---|---|---|---|---|
| Revenue | ₹4,516.6 Cr | ₹4,173 Cr | ₹4,295.5 Cr | N/A | N/A | ₹3,821.4 Cr |
| Profit before tax | ₹247.5 Cr | ₹-67.8 Cr | ₹171.3 Cr | N/A | N/A | ₹155.9 Cr |
| Profit after tax | ₹198.6 Cr | ₹-51.8 Cr | ₹132.8 Cr | N/A | N/A | ₹81.1 Cr |
| Finance cost | ₹231.5 Cr | ₹209.9 Cr | ₹272.2 Cr | N/A | N/A | ₹223.4 Cr |
| Impairment | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS | ₹0.79 | ₹1.08 | ₹0.66 | N/A | N/A | ₹0.21 |
Accounting lens
Research frameworkWhat deserves analyst attention
Confirm quarterly, year-to-date and annual periods before calculating growth. The table preserves the exchange period labels.
Treat scope changes as breaks in comparability and open the linked XBRL before relying on a trend.
Sector metrics and accounting choices require additional facts beyond this common cross-company layer.